Quipt Home MedicalQIPT.VCOMMENTJan 15, 2024Stock price when the opinion was issued
As of Jun 20, 2023. Market Open.
CEO is a really good operator, but stock just doesn't seem to get any love. Numbers have been OK, but not any really great growth. Looks good on EBITDA (due to equipment depreciation), but not on earnings. Takeout rumours always swirl but he won't buy on that basis alone, praying for a takout, if the fundamentals aren't there.
The trend of keeping people out of hospitals sounds good, but he's a numbers guy and it doesn't have the growth he wants.
Extremely challenged, though business continues to do well. One headwind is weight loss drug success makes investors concerned that respiratory issues will go away. That won't happen. Advertising practices under scrutiny, and there could be a fine.
Numbers continue to grow. Valuation lower than historically.
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Company recently acquired (Great Elm). At $80M it is a sizeable deal, but adds $60M in revenue and $13M in EBITDA. Should be $2M in cost savings and it is accretive to cash flow. The market likes the deal. Good earnings growth is expected. Unlock Premium - Try 5i Free
This used to be called Patient Home Monitoring at one point. It is very cheap, has been performing and executing acquisitions pretty consistently. The CEO and management have done very well. The small cap health care sector is quiet but due to Quipt's good value it could be a takeover candidate.